Belzutifan and Abemaciclib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Belzutifan
Abemaciclib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on with these two cancer medicines. Belzutifan (Welireg) can speed up the liver enzyme (called CYP3A4) that breaks down abemaciclib (Verzenio). When abemaciclib is cleared out faster, its blood level can drop, which may make it less effective at doing its job.
Right now this concern is based on how the drugs behave in theory and in similar studies, not on lots of real-world reports with this exact pair. Please don't change anything on your own. Your cancer care team knows how to handle this by adjusting your dose if needed and keeping a closer eye on how you're doing. Bring it up at your next visit.
Mechanism: Belzutifan induces CYP3A4. Abemaciclib is a CYP3A4 substrate, so its metabolism may increase, lowering abemaciclib exposure (AUC/Cmax) and potentially reducing antineoplastic efficacy. Neither agent's activity depends on prodrug conversion here.
- Direction: reduced abemaciclib effect
- Magnitude: extrapolated from midazolam (AUC decreased ~40%, Cmax ~34%; up to ~70% AUC reduction predicted in dual UGT2B17/CYP2C19 poor metabolizers of belzutifan)
- Onset: unspecified
- Evidence: theoretical
Management: Avoid the combination where feasible. If unavoidable, abemaciclib dose may need individualized upward adjustment with closer monitoring of disease response and tolerability.
What happens
Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI
Interaction Deep Dive
Belzutifan should not be given together with sensitive CYP3A4 substrates when even a small drop in the substrate's concentration could cause it to fail therapeutically. When such combined use is unavoidable, raise the dose of the sensitive CYP3A4 substrate as required. Giving belzutifan alongside CYP3A4 substrates may lower the exposure of CYP3A4 substrates with an NTI, potentially diminishing the effectiveness of those substrates. This effect may be greater in patients who are poor metabolizers of both UGT2B17 and CYP2C19. When belzutifan was administered with midazolam (a sensitive CYP3A4 substrate), the midazolam AUC fell by 40% and the Cmax by 34%. In patients with elevated belzutifan concentrations (for example, dual poor metabolizers), the midazolam AUC is projected to drop by as much as 70%1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism by belzutifan
How to manage this interaction
Keep taking both medicines exactly as prescribed unless your oncology team tells you otherwise. Because belzutifan can lower the amount of abemaciclib in your body, here is how a care team typically manages this:
- Where possible, they may avoid using the two together and choose an alternative.
- If both are needed, your abemaciclib dose may need to be adjusted and individualized by your care team.
- They may monitor you more closely to make sure your treatment stays effective.
Ask your pharmacist or oncologist whether this combination applies to you, especially before any dose changes, and report any new symptoms.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) Giving belzutifan 120 mg once daily together with midazolam (a sensitive CYP3A4 substrate) reduced the midazolam AUC by 40% and the Cmax by 34%. In patients with higher belzutifan concentrations (for example, dual poor metabolizers), midazolam AUC is predicted to fall by up to 70% 1.
Common questions
Can I take Belzutifan and Abemaciclib together?
Belzutifan may lower abemaciclib levels and make it less effective; don't change anything yourself, but ask your oncology team, who can adjust the dose and monitor you more closely. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Belzutifan and Abemaciclib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Belzutifan and Abemaciclib interaction managed?
Keep taking both medicines exactly as prescribed unless your oncology team tells you otherwise. Because belzutifan can lower the amount of abemaciclib in your body, here is how a care team typically manages this: Where possible, they may avoid using the two together and choose an alternative. If both are needed, your abemaciclib dose may need to be adjusted and individualized by your care team. Th… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Belzutifan or Abemaciclib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: WELIREG(R) oral tablets, belzutifan oral tablets. Merck Sharp & Dohme LLC (per manufacturer), Rahway, NJ, 2025. DailyMed
Keep reading about Belzutifan
Keep reading about Abemaciclib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist